Thread for Tirzepatide studies and personal experiences

[beefnewton]

What does pre-bed do? I've always just taken it in morning.

 

[J2048b]

https://www.reddit.com/r/Mounjaro/s/LOv9G4MtA6

Sent from my iPhone using Tapatalk

 

[MR. BMJ]

Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity

This cohort study compares treatment-associated weight loss and rates of gastrointestinal adverse events among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes in a clinical setting.

jamanetwork.com

FULL STUDY IN LINK

July 8, 2024

Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity​

Patricia J. Rodriguez, PhD1; Brianna M. Goodwin Cartwright, MS1; Samuel Gratzl, PhD1; et alRajdeep Brar, MD1; Charlotte Baker, DrPH1; Ty J. Gluckman, MD2; Nicholas L. Stucky, MD1

Author Affiliations Article Information

JAMA Intern Med. Published online July 8, 2024. doi:10.1001/jamainternmed.2024.2525

Key Points
Question How does weight loss differ between patients receiving tirzepatide compared with semaglutide among a clinical population of adults with overweight or obesity?

Findings In this cohort study of 18 386 propensity-score matched patients initiating tirzepatide or semaglutide labeled for type 2 diabetes, discontinuation was common; most achieved weight loss of 5% or greater within 1 year of treatment.

Meaning Although most adults with overweight or obesity experienced 5% or greater weight loss with treatment, the benefit was greater with tirzepatide.

Abstract
Importance Although tirzepatide and semaglutide were shown to reduce weight in randomized clinical trials, data from head-to-head comparisons in populations with overweight or obesity are not yet available.

Objective To compare on-treatment weight loss and rates of gastrointestinal adverse events (AEs) among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes (T2D) in a clinical setting.

Design, Setting, and Participants In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems. On-treatment weight outcomes through November 3, 2023, were assessed. Adults with overweight or obesity and regular care in the year before initiation, no prior glucagon-like peptide 1 receptor agonist receptor agonist use, a prescription within 60 days prior to initiation, and an available baseline weight were identified. The analysis was completed on April 3, 2024.

Exposures Tirzepatide or semaglutide in formulations labeled for T2D, on or off label.

Main Outcomes and Measures On-treatment weight change in a propensity score–matched population, assessed as hazard of achieving 5% or greater, 10% or greater, and 15% or greater weight loss, and percentage change in weight at 3, 6, and 12 months. Hazards of gastrointestinal AEs were compared.

Results Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching. The mean (SD) age was 52.0 (12.9) years, 12 970 were female (70.5%), 14 182 were white (77.1%), 2171 Black (11.8%), 354 Asian (1.9%), 1679 were of other or unknown race, and 9563 (52.0%) had T2D. The mean (SD) baseline weight was 110 (25.8) kg. Follow-up was ended by discontinuation for 5140 patients (55.9%) receiving tirzepatide and 4823 (52.5%) receiving semaglutide. Patients receiving tirzepatide were significantly more likely to achieve weight loss (≥5%; hazard ratio

---

, 1.76, 95% CI, 1.68, 1.84; ≥10%; HR, 2.54; 95% CI, 2.37, 2.73; and ≥15%; HR, 3.24; 95% CI, 2.91, 3.61). On-treatment changes in weight were larger for patients receiving tirzepatide at 3 months (difference, −2.4%; 95% CI −2.5% to −2.2%), 6 months (difference, −4.3%; 95% CI, −4.7% to −4.0%), and 12 months (difference, −6.9%; 95% CI, −7.9% to −5.8%). Rates of gastrointestinal AEs were similar between groups.

Conclusions and Relevance In this population of adults with overweight or obesity, use of tirzepatide was associated with significantly greater weight loss than semaglutide. Future study is needed to understand differences in other important outcomes.

 

[Yano]

Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity

This cohort study compares treatment-associated weight loss and rates of gastrointestinal adverse events among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes in a clinical setting.

jamanetwork.com

FULL STUDY IN LINK

July 8, 2024

Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity​

Patricia J. Rodriguez, PhD1; Brianna M. Goodwin Cartwright, MS1; Samuel Gratzl, PhD1; et alRajdeep Brar, MD1; Charlotte Baker, DrPH1; Ty J. Gluckman, MD2; Nicholas L. Stucky, MD1

Author Affiliations Article Information

JAMA Intern Med. Published online July 8, 2024. doi:10.1001/jamainternmed.2024.2525

Key Points
Question How does weight loss differ between patients receiving tirzepatide compared with semaglutide among a clinical population of adults with overweight or obesity?

Findings In this cohort study of 18 386 propensity-score matched patients initiating tirzepatide or semaglutide labeled for type 2 diabetes, discontinuation was common; most achieved weight loss of 5% or greater within 1 year of treatment.

Meaning Although most adults with overweight or obesity experienced 5% or greater weight loss with treatment, the benefit was greater with tirzepatide.

Abstract
Importance Although tirzepatide and semaglutide were shown to reduce weight in randomized clinical trials, data from head-to-head comparisons in populations with overweight or obesity are not yet available.

Objective To compare on-treatment weight loss and rates of gastrointestinal adverse events (AEs) among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes (T2D) in a clinical setting.

Design, Setting, and Participants In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems. On-treatment weight outcomes through November 3, 2023, were assessed. Adults with overweight or obesity and regular care in the year before initiation, no prior glucagon-like peptide 1 receptor agonist receptor agonist use, a prescription within 60 days prior to initiation, and an available baseline weight were identified. The analysis was completed on April 3, 2024.

Exposures Tirzepatide or semaglutide in formulations labeled for T2D, on or off label.

Main Outcomes and Measures On-treatment weight change in a propensity score–matched population, assessed as hazard of achieving 5% or greater, 10% or greater, and 15% or greater weight loss, and percentage change in weight at 3, 6, and 12 months. Hazards of gastrointestinal AEs were compared.

Results Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching. The mean (SD) age was 52.0 (12.9) years, 12 970 were female (70.5%), 14 182 were white (77.1%), 2171 Black (11.8%), 354 Asian (1.9%), 1679 were of other or unknown race, and 9563 (52.0%) had T2D. The mean (SD) baseline weight was 110 (25.8) kg. Follow-up was ended by discontinuation for 5140 patients (55.9%) receiving tirzepatide and 4823 (52.5%) receiving semaglutide. Patients receiving tirzepatide were significantly more likely to achieve weight loss (≥5%; hazard ratio

---

, 1.76, 95% CI, 1.68, 1.84; ≥10%; HR, 2.54; 95% CI, 2.37, 2.73; and ≥15%; HR, 3.24; 95% CI, 2.91, 3.61). On-treatment changes in weight were larger for patients receiving tirzepatide at 3 months (difference, −2.4%; 95% CI −2.5% to −2.2%), 6 months (difference, −4.3%; 95% CI, −4.7% to −4.0%), and 12 months (difference, −6.9%; 95% CI, −7.9% to −5.8%). Rates of gastrointestinal AEs were similar between groups.

Conclusions and Relevance In this population of adults with overweight or obesity, use of tirzepatide was associated with significantly greater weight loss than semaglutide. Future study is needed to understand differences in other important outcomes.

Friend of mine was put on Ozempic (tirz) and in the past year shes dropped 100 lbs and managed to get her diabetes controlled for the first time. She says on occasion it makes her feel sick to her stomach but for as much as it helps its worth it for her to keep taking.

 

[Bewley595]

What are thoughts on dosage? I read 2.5 mg for first 4 weeks but my wife over responds to most medications. Should she start at 1 mg?